Pimitespib not checked

Taiho · TAS-116

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in…”In the company’s words, NCT05245968 on ClinicalTrials.gov
Tested for
Gastrointestinal Stromal Tumors, Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer and 2 more
Main trialPhase 1
“This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged to be refractory to imatinib, estimate the recommended dose, evaluate safety and pharmacokinetics, and observe the antitumor effect. Expansion part consists of 3 arms. In Arm A, the efficacy and safety will be evaluated, which of the combination of pimitespib and imatinib in patients with GIST who have failed imatinib at doses below the MTD determined in Dose…”In the company’s words, NCT05245968 on ClinicalTrials.gov
Other names
TAS-116

Other drugs for Gastrointestinal Stromal Tumors

All 13 drugs for Gastrointestinal Stromal Tumors

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Dec 2026 A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Phase 1Recruiting Jun 2027 AB122 Platform Study
Phase 1Completed 3 May 2019 A Study of TAS-116 in Patients With Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pimitespib

Following is part of Solo: you see every change to Pimitespib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in